{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T19:32:45Z","timestamp":1783366365785,"version":"3.54.6"},"reference-count":79,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004895","name":"European Social Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004895","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1016\/j.cca.2014.07.040","type":"journal-article","created":{"date-parts":[[2014,8,12]],"date-time":"2014-08-12T23:34:55Z","timestamp":1407886495000},"page":"35-42","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["Human epididymis protein 4 (HE4) in laboratory medicine and an algorithm in renal disorders"],"prefix":"10.1016","volume":"438","author":[{"given":"J\u00e1nos","family":"Kappelmayer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e9ter","family":"Antal-Szalm\u00e1s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"B\u00e9la","family":"Nagy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cca.2014.07.040_bb0005","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1472-6874-11-31","article-title":"Symptom interpretation and health care seeking in ovarian cancer","volume":"11","author":"Seibaek","year":"2011","journal-title":"BMC Womens Health"},{"key":"10.1016\/j.cca.2014.07.040_bb0010","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.ygyno.2013.12.017","article-title":"High-volume ovarian cancer care: survival impact and disparities in access for advanced-stage disease","volume":"132","author":"Bristow","year":"2014","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.cca.2014.07.040_bb0015","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ygyno.2011.06.033","article-title":"Prognostic factors for early-stage epithelial ovarian cancer, treated with adjuvant carboplatin\/paclitaxel chemotherapy: a single institution experience","volume":"123","author":"Bamias","year":"2011","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.cca.2014.07.040_bb0020","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.ygyno.2013.11.030","article-title":"Ovarian cancer screening\u2014current status, future directions","volume":"132","author":"Menon","year":"2014","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.cca.2014.07.040_bb0025","first-page":"423","article-title":"Hereditary breast cancer: beyond BRCA genetic analysis; PALB2 emerges","volume":"50","author":"Poumpouridou","year":"2011","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.cca.2014.07.040_bb0030","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1038\/sj.bjc.6603725","article-title":"No efficacy of annual gynaecological screening in BRCA1\/2 mutation carriers; an observational follow-up study","volume":"96","author":"Hermsen","year":"2007","journal-title":"Br J Cancer"},{"key":"10.1016\/j.cca.2014.07.040_bb0035","first-page":"3695","article-title":"The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma","volume":"63","author":"Hellstr\u00f6m","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.cca.2014.07.040_bb0040","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.ygyno.2007.10.017","article-title":"The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass","volume":"108","author":"Moore","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.cca.2014.07.040_bb0045","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1373\/clinchem.2010.157073","article-title":"Comparison of serum human epididymis protein 4 with cancer antigen 125 as a tumor marker in patients with malignant and nonmalignant diseases","volume":"57","author":"Escudero","year":"2011","journal-title":"Clin Chem"},{"key":"10.1016\/j.cca.2014.07.040_bb0050","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1515\/CCLM.2011.709","article-title":"The diagnostic accuracy of two human epididymis protein 4 (HE4) testing systems in combination with CA125 in the differential diagnosis of ovarian masses","volume":"49","author":"Lenhard","year":"2011","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.cca.2014.07.040_bb0055","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1515\/cclm-2012-0097","article-title":"Human epididymis protein 4 (HE4) in benign and malignant diseases","volume":"50","author":"Hertlein","year":"2012","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.cca.2014.07.040_bb0060","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1177\/172460089801300402","article-title":"CA125: the past and the future","volume":"13","author":"Bast","year":"1998","journal-title":"Int J Biol Markers"},{"key":"10.1016\/j.cca.2014.07.040_bb0065","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1093\/jnci\/djr359","article-title":"Potential role of HE4 in multimodal screening for epithelial ovarian cancer","volume":"103","author":"Urban","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.cca.2014.07.040_bb0070","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0378-1119(99)00342-X","article-title":"Comparative hybridization of an array of 21,500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas","volume":"238","author":"Schummer","year":"1999","journal-title":"Gene"},{"key":"10.1016\/j.cca.2014.07.040_bb0075","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0378-1119(99)00035-9","article-title":"Monitoring gene expression profile changes in ovarian carcinomas using cDNA microarray","volume":"229","author":"Wang","year":"1999","journal-title":"Gene"},{"key":"10.1016\/j.cca.2014.07.040_bb0080","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1095\/biolreprod45.2.350","article-title":"A major human epididymis-specific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitors","volume":"45","author":"Kirchhoff","year":"1991","journal-title":"Biol Reprod"},{"key":"10.1016\/j.cca.2014.07.040_bb0085","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1038\/sj.onc.1205363","article-title":"The putative ovarian tumour marker gene HE4 (WFDC2), is expressed in normal tissues and undergoes complex alternative splicing to yield multiple protein isoforms","volume":"21","author":"Bingle","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.cca.2014.07.040_bb0090","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1042\/bj20020869","article-title":"A locus on human chromosome 20 contains several genes expressing protease inhibitor domains with homology to whey acidic protein","volume":"368","author":"Clauss","year":"2002","journal-title":"Biochem J"},{"key":"10.1016\/j.cca.2014.07.040_bb0095","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1042\/bj3400569","article-title":"The trappin gene family: proteins defined by an N-terminal transglutaminase substrate domain and a C-terminal four-disulphide core","volume":"340","author":"Schalkwijk","year":"1999","journal-title":"Biochem J"},{"key":"10.1016\/j.cca.2014.07.040_bb0100","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/modpathol.3800612","article-title":"Comprehensive analysis of HE4 expression in normal and malignant human tissues","volume":"19","author":"Galgano","year":"2006","journal-title":"Mod Pathol"},{"key":"10.1016\/j.cca.2014.07.040_bb0105","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.ejogrb.2011.05.021","article-title":"Prognostic significance of human epididymis protein 4 in epithelial ovarian cancer","volume":"158","author":"Paek","year":"2011","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.cca.2014.07.040_bb0110","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ygyno.2008.08.031","article-title":"A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass","volume":"112","author":"Moore","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.cca.2014.07.040_bb0115","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1038\/sj.bjc.6605011","article-title":"Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts","volume":"100","author":"Huhtinen","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1016\/j.cca.2014.07.040_bb0120","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.ygyno.2010.02.005","article-title":"Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass","volume":"117","author":"Nolen","year":"2010","journal-title":"Gynecol Oncol"},{"issue":"351","key":"10.1016\/j.cca.2014.07.040_bb0125","first-page":"e1","article-title":"Serum HE4 levels are less frequently elevated than CA125 in women with benign gynecologic disorders","volume":"206","author":"Moore","year":"2012","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.cca.2014.07.040_bb0130","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s13277-009-0015-y","article-title":"HE4: a new potential early biomarker for the recurrence of ovarian cancer","volume":"31","author":"Anastasi","year":"2010","journal-title":"Tumour Biol"},{"key":"10.1016\/j.cca.2014.07.040_bb0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/B978-0-12-405211-6.00001-2","article-title":"Human epididymis protein 4 in cancer diagnostics: a promising and reliable tumor marker","volume":"59","author":"Speeckaert","year":"2013","journal-title":"Adv Clin Chem"},{"key":"10.1016\/j.cca.2014.07.040_bb0140","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1136\/jclinpath-2012-201031","article-title":"Serum human epididymis protein 4 vs carbohydrate antigen 125 for ovarian cancer diagnosis: a systematic review","volume":"66","author":"Ferraro","year":"2013","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.cca.2014.07.040_bb0145","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/j.cca.2011.04.028","article-title":"HE4 and epithelial ovarian cancer: comparison and clinical evaluation of two immunoassays and a combination algorithm","volume":"412","author":"Ruggeri","year":"2011","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.cca.2014.07.040_bb0150","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1111\/j.1471-0528.1990.tb02448.x","article-title":"A risk of malignancy index incorporating CA125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer","volume":"97","author":"Jacobs","year":"1990","journal-title":"Br J Obstet Gynaecol"},{"key":"10.1016\/j.cca.2014.07.040_bb0155","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1007\/s13277-012-0440-1","article-title":"An ovarian cancer malignancy risk index composed of HE4, CA125, ultrasonographic score, and menopausal status: use in differentiation of ovarian cancers and benign lesions","volume":"33","author":"Macuks","year":"2012","journal-title":"Tumour Biol"},{"issue":"228","key":"10.1016\/j.cca.2014.07.040_bb0160","first-page":"e1","article-title":"Comparison of a novel multiple marker assay vs the risk of malignancy index for the prediction of epithelial ovarian cancer in patients with a pelvic mass","volume":"203","author":"Moore","year":"2010","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.cca.2014.07.040_bb0165","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1515\/CCLM.2011.075","article-title":"The ROMA (risk of ovarian malignancy algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful?","volume":"49","author":"Montagnana","year":"2011","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.cca.2014.07.040_bb0170","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.ygyno.2009.10.087","article-title":"Use of a symptom index, CA125, and HE4 to predict ovarian cancer","volume":"116","author":"Andersen","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.cca.2014.07.040_bb0175","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1016\/j.ejca.2011.12.003","article-title":"Subjective assessment by ultrasound is superior to the risk of malignancy index (RMI) or the risk of ovarian malignancy algorithm (ROMA) in discriminating benign from malignant adnexal masses","volume":"48","author":"Van Gorp","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.cca.2014.07.040_bb0180","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1515\/CCLM.2011.694","article-title":"Increased plasma concentrations of tumour markers in the absence of neoplasia","volume":"49","author":"Trap\u00e9","year":"2011","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.cca.2014.07.040_bb0185","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S1470-2045(06)70579-4","article-title":"Proteins with whey-acidic-protein motifs and cancer","volume":"7","author":"Bouchard","year":"2006","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cca.2014.07.040_bb0190","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.bbrc.2012.02.008","article-title":"Human epididymis protein 4 (HE4) plays a key role in ovarian cancer cell adhesion and motility","volume":"419","author":"Lu","year":"2012","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.cca.2014.07.040_bb0195","doi-asserted-by":"crossref","first-page":"6026","DOI":"10.3390\/ijms14036026","article-title":"HE4 (WFDC2) promotes tumor growth in endometrial cancer cell lines","volume":"14","author":"Li","year":"2013","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.cca.2014.07.040_bb0200","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/nm.2989","article-title":"Identification of human epididymis protein-4 as a fibroblast-derived mediator of fibrosis","volume":"19","author":"LeBleu","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.cca.2014.07.040_bb0205","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1515\/cclm-2012-0373","article-title":"HE4 Study Group. HE4 in gynecological cancers: report of a European investigators and experts meeting","volume":"50","author":"Plebani","year":"2012","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.cca.2014.07.040_bb0210","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1038\/bjc.2011.109","article-title":"Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients","volume":"104","author":"Bignotti","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.cca.2014.07.040_bb0215","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1515\/cclm-2011-0757","article-title":"Human epididymis protein 4 as a serum marker for diagnosis of endometrial carcinoma and prediction of clinical outcome","volume":"50","author":"Zanotti","year":"2012","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.cca.2014.07.040_bb0220","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.ygyno.2011.10.025","article-title":"Correlation of serum HE4 with tumor size and myometrial invasion in endometrial cancer","volume":"124","author":"Kalogera","year":"2012","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.cca.2014.07.040_bb0225","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ygyno.2008.04.002","article-title":"Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus","volume":"110","author":"Moore","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.cca.2014.07.040_bb0230","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1200\/JCO.2008.19.2484","article-title":"Development of a multimarker assay for early detection of ovarian cancer","volume":"28","author":"Yurkovetsky","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cca.2014.07.040_bb0235","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/1465-9921-7-61","article-title":"WFDC2 (HE4): a potential role in the innate immunity of the oral cavity and respiratory tract and the development of adenocarcinomas of the lung","volume":"7","author":"Bingle","year":"2006","journal-title":"Respir Res"},{"key":"10.1016\/j.cca.2014.07.040_bb0240","first-page":"4779","article-title":"HE4 expression can be associated with lymph node metastases and disease-free survival in breast cancer","volume":"30","author":"Kamei","year":"2010","journal-title":"Anticancer Res"},{"key":"10.1016\/j.cca.2014.07.040_bb0245","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s13277-011-0252-8","article-title":"Splice variant HE4-V3 expression is associated with favorable prognosis in pulmonary adenocarcinoma","volume":"33","author":"Tokuishi","year":"2012","journal-title":"Tumour Biol"},{"key":"10.1016\/j.cca.2014.07.040_bb0250","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s13277-010-0118-5","article-title":"Prognostic significance of HE4 expression in pulmonary adenocarcinoma","volume":"32","author":"Yamashita","year":"2011","journal-title":"Tumour Biol"},{"key":"10.1016\/j.cca.2014.07.040_bb0255","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1007\/s13277-012-0356-9","article-title":"Serum HE4 as a diagnostic and prognostic marker for lung cancer","volume":"33","author":"Iwahori","year":"2012","journal-title":"Tumour Biol"},{"key":"10.1016\/j.cca.2014.07.040_bb0260","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1007\/s13277-012-0499-8","article-title":"Serum level of HE4 is closely associated with pulmonary adenocarcinoma progression","volume":"3","author":"Yamashita","year":"2012","journal-title":"Tumour Biol"},{"key":"10.1016\/j.cca.2014.07.040_bb0265","doi-asserted-by":"crossref","DOI":"10.1515\/cclm-2014-0041","article-title":"Serum human epididymis protein 4 (HE4) as a tumor marker in men with lung cancer","author":"Nagy","year":"2014","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.cca.2014.07.040_bb0270","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.canlet.2010.03.013","article-title":"Detection of the HE4 protein in urine as a biomarker for ovarian neoplasms","volume":"296","author":"Hellstr\u00f6m","year":"2010","journal-title":"Cancer Lett"},{"key":"10.1016\/j.cca.2014.07.040_bb0275","doi-asserted-by":"crossref","first-page":"4695","DOI":"10.7314\/APJCP.2012.13.9.4695","article-title":"Urinary concentrations of human epidydimis secretory protein 4 (He4) in the diagnosis of ovarian cancer: a case-control study","volume":"13","author":"Macuks","year":"2012","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1016\/j.cca.2014.07.040_bb0280","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.ygyno.2013.05.028","article-title":"Anti-HE4 antibodies in infertile women and women with ovarian cancer","volume":"130","author":"Hellstr\u00f6m","year":"2013","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.cca.2014.07.040_bb0285","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1517\/17530059.2011.559459","article-title":"Two novel biomarkers, mesothelin and HE4, for diagnosis of ovarian carcinoma","volume":"5","author":"Hellstr\u00f6m","year":"2011","journal-title":"Expert Opin Med Diagn"},{"key":"10.1016\/j.cca.2014.07.040_bb0290","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s13277-011-0256-4","article-title":"Human epididymis protein 4 reference limits and natural variation in a Nordic reference population","volume":"33","author":"Bolstad","year":"2012","journal-title":"Tumour Biol"},{"issue":"349","key":"10.1016\/j.cca.2014.07.040_bb0295","first-page":"e1","article-title":"Serum levels of the ovarian cancer biomarker HE4 are decreased in pregnancy and increase with age","volume":"206","author":"Moore","year":"2012","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.cca.2014.07.040_bb0300","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1080\/00365510802126836","article-title":"Reference intervals for carcinoembryonic antigen (CEA), CA125, MUC1, Alfa-foeto-protein (AFP), neuron-specific enolase (NSE) and CA19.9 from the NORIP study","volume":"68","author":"Bjerner","year":"2008","journal-title":"Scand J Clin Lab Invest"},{"key":"10.1016\/j.cca.2014.07.040_bb0305","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1136\/thx.41.1.17","article-title":"Effect of cigarette smoking, pulmonary inflammation, and lung disease on concentrations of carcinoembryonic antigen in serum and secretions","volume":"41","author":"Stockley","year":"1986","journal-title":"Thorax"},{"key":"10.1016\/j.cca.2014.07.040_bb0310","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s13277-010-0049-1","article-title":"Ovarian tumor marker HE4 is differently expressed during the phases of the menstrual cycle in healthy young women","volume":"31","author":"Anastasi","year":"2010","journal-title":"Tumour Biol"},{"key":"10.1016\/j.cca.2014.07.040_bb0315","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1111\/j.1572-0241.1999.01152.x","article-title":"Cancer antigen 125: a sensitive marker of ascites in patients with liver cirrhosis","volume":"94","author":"Zuckerman","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cca.2014.07.040_bb0320","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.5588\/ijtld.13.0058","article-title":"Evaluating the clinical significance of serum HE4 levels in lung cancer and pulmonary tuberculosis","volume":"17","author":"Liu","year":"2013","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.cca.2014.07.040_bb0325","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1159\/000186247","article-title":"Tumor markers in chronic renal failure and hemodialysis patients","volume":"57","author":"Cases","year":"1991","journal-title":"Nephron"},{"key":"10.1016\/j.cca.2014.07.040_bb0330","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1159\/000048687","article-title":"S-100 protein serum levels in patients with benign and malignant diseases: false-positive results related to liver and renal function","volume":"23","author":"Molina","year":"2002","journal-title":"Tumour Biol"},{"key":"10.1016\/j.cca.2014.07.040_bb0335","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1093\/ndt\/18.3.598","article-title":"Percent-free prostate specific antigen is elevated in men on haemodialysis or peritoneal dialysis treatment","volume":"18","author":"Bruun","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.cca.2014.07.040_bb0340","doi-asserted-by":"crossref","first-page":"210","DOI":"10.3109\/0886022X.2013.859528","article-title":"CA125 levels and left ventricular function in patients with end-stage renal disease on maintenance hemodialysis","volume":"36","author":"Yilmaz","year":"2014","journal-title":"Ren Fail"},{"key":"10.1016\/j.cca.2014.07.040_bb0345","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1258\/acb.2011.011258","article-title":"Elevated human epididymis protein 4 concentrations in chronic kidney disease","volume":"49","author":"Nagy","year":"2012","journal-title":"Ann Clin Biochem"},{"key":"10.1016\/j.cca.2014.07.040_bb0350","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1093\/ajcp\/106.1.118","article-title":"Cardiac troponin T is elevated in asymptomatic patients with chronic renal failure","volume":"106","author":"Frankel","year":"1996","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.cca.2014.07.040_bb0355","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1093\/clinchem\/46.9.1345","article-title":"Cardiac troponin T and I in end-stage renal failure","volume":"46","author":"Wayand","year":"2000","journal-title":"Clin Chem"},{"key":"10.1016\/j.cca.2014.07.040_bb0360","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0009-8981(97)00251-9","article-title":"Troponin T: a sensitive and specific diagnostic and prognostic marker of myocardial damage","volume":"272","author":"Gerhardt","year":"1998","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.cca.2014.07.040_bb0365","doi-asserted-by":"crossref","first-page":"286","DOI":"10.5830\/CVJA-2013-055","article-title":"Diagnostic and prognostic values of B-type natriuretic peptides (BNP) and N-terminal fragment brain natriuretic peptides (NT-pro-BNP)","volume":"24","author":"Maries","year":"2013","journal-title":"Cardiovasc J Afr"},{"key":"10.1016\/j.cca.2014.07.040_bb0370","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1515\/cclm-2013-0660","article-title":"Could kidney glomerular filtration impairment represent the \u201cAchilles heel\u201d of HE4 serum marker? A possible further implication","volume":"52","author":"Gizzo","year":"2014","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.cca.2014.07.040_bb0375","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.cca.2013.11.002","article-title":"Enzymatic creatinine assays allow estimation of glomerular filtration rate in stages 1 and 2 chronic kidney disease using CKD-EPI equation","volume":"428","author":"Kuster","year":"2014","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.cca.2014.07.040_bb0380","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.cca.2012.10.058","article-title":"Detection and monitoring of ovarian cancer","volume":"415","author":"Su","year":"2013","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.cca.2014.07.040_bb0385","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s13277-013-1190-4","article-title":"A critical review on HE4 performance in endometrial cancer: where are we now?","volume":"35","author":"Angioli","year":"2014","journal-title":"Tumour Biol"},{"key":"10.1016\/j.cca.2014.07.040_bb0390","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1515\/cclm-2012-0683","article-title":"Human epididymis protein 4: the start of a post-ROMAn era?","volume":"50","author":"Melichar","year":"2012","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.cca.2014.07.040_bb0395","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.ygyno.2014.03.575","article-title":"The clinical and diagnostic role of microRNAs in ovarian carcinoma","volume":"133","author":"Davidson","year":"2014","journal-title":"Gynecol Oncol"}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898114003362?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898114003362?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T14:45:21Z","timestamp":1757861121000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898114003362"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":79,"alternative-id":["S0009898114003362"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2014.07.040","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2015,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Human epididymis protein 4 (HE4) in laboratory medicine and an algorithm in renal disorders","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2014.07.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}